Buyse M. Invited lecture at the ESMO Symposium on Cancer Biology for Clinicians.
The list below includes presentations at scientific meetings and abstracts for 2008 .
Click on the links at the bottom of the page to view the list of archived presentations.
- 2010
November 27, 2010
Statistical design solutions - How statistics can help in the design of targeted trials
Nice, France
October 14, 2010
The role of independent statisticians in clinical development - current challenges and a vision for the future
Buyse M. Invited lecture at the Scientific Day organized by GlaxoSmithKline Biologicals.
Wavre, Belgium
October 8, 2010
The importance of conducting well-designed clinical trials
Buyse M. Invited lecture at the ESMO Young Oncologists Masterclass, 35th Congress of the European Society for Medical Oncology.
Milan, Italy
October 4, 2010
Comment faire évoluer le paradigme du développement clinique et son découpage en phase I, II, III, IV ?
Buyse M. Table Ronde at the XXVIèmes Rencontres Nationales de Pharmacologie Clinique de Giens.
Giens, France
September 20, 2010
The surrogate threshold effect for progression-free survival in oncology.
Buyse M. Invited lecture at the FDA / Industry Statistics Workshop.
Washington DC, US
September 12, 2010
Clinical trial methodology
Buyse M. Invited lectures at the Australia and Asia Pacific Clinical Oncology Research Development (ACORD) Workshop.
Brisbane, Australia
September 6, 2010
Methodology in trial design and meta-analysis
Buyse M. Invited lectures at the Vito Distante Project in Breast Cancer Clinical Research.
Luca, Italy
August 2, 2010
Evolution in methods of evaluating surrogate endpoints in meta-analytic framework
Tomasz Burzykowski. Topic Contributed Session (Biopharmaceutical Section), 2010 Joint Statistical Meetings.
Vancouver, Canada
July 2, 2010
A new measure of treatment benefit in randomized trials, with applications to gastrointestinal cancer
Buyse M., keynote lecture 2 at the Session XII ESMO session: Focus on young medical oncologist.
Barcelona, Spain.
June 28, 2010
Designs for randomized clinical trials, and methods of randomization
Buyse M. Invited lecture at the European Course for Pharmaceutical Medicine.
Basel, Switzerland
June 24, 2010
Statistical methods for clinical trials in the era of individualized medicine
Buyse M. Invited lecture at the European Statistical Meeting on Oncology organized by the Basel Biometric Section ( BBS) in cooperation with the European Federation of Statisticians.
Basel Switzerland
June 15, 2010
Presentation of the ANed Biometry Award
Buyse M. Presentation at the Biostatistics Symposium "Inference in Clinical Research".
Utrecht, the Netherlands
May 24, 2010
Comparaisons généralisées par paires pour la comparaison de deux groupes
Buyse M. Invited lecture at the 42èmes Journées de Statistique of the Société Française de Statistique.
Marseillle, France
May 23, 2010
Short course on Survival Analysis
Tomasz Burzykowski invited lecture at the Medical University of Bialystok, Poland.
Bialystok, Poland
May 17, 2010
Practical Matters for Futility Analyses
Buyse M. Invited lecture at the 31st Meeting of the Society for Clinical Trials.
Baltimore, MD, US
May 16, 2010
A new measure of treatment benefit in clinical trials
Buyse M. Invited lecture at the 31st Meeting of the Society for Clinical Trials.
Baltimore, MD, US
May 16, 2010
Endpoints, Strength of Evidence, and the FDA Approval Process in Oncology
Buyse M. Invited lecture at the 31st Meeting of the Society for Clinical Trials.
Baltimore, MD, US
May 16, 2010
Short course on Survival Analysis
Tomasz Burzykowski invited lecture at the Medical University of Bialystok, Poland.
Bialystok, Poland
May 6, 2010
Methodology in biomarkers research and validation
Buyse M. . Invited lecture at the pre-IMPAKT Training Course.
Brussels, Belgium
May 4, 2010
A generalization of the Wilcoxon-Mann-Whitney test for the comparison of two samples
Buyse M. Invited lecture at the Meeting on "Mathematics and Industry" organized by the Société de Mathématiques Appliquées et Industrielles and the Société Française de Statistique.
Rennes, France
April 14, 2010
A new measure of treatment benefit in clinical trials
Buyse M. Invited lecture at the Wales Cancer Conference.
Cardiff, Wales
April 12, 2010
Clinical Trial Methodology.
Buyse M. Course given at the Tata Memorial Hospital.
Mumbai, India
March 24, 2010
Statistical considerations for biomarker research
Buyse M. Invited teaching lecture at the 7th European Breast Cancer Conference.
Barcelona, Spain
March 8, 2010
Integrating biomarkers in clinical research - Statistical considerations
Buyse M. Invited lecture at the AACR Conference on "Advances in Cancer Research: From the Laboratory to the Clinic".
Dead Sea, Jordan
February 4, 2010
A quel moment les résultats d'un essai thérapeutique peuvent-ils être considérés comme définitifs en traitement adjuvant ? Critères statistiques.
Buyse M. Invited lecture at the Journées d'Echanges et d'Autoévaluation en Oncologie.
Paris, France
February 1, 2010
A novel universal measure of treatment benefit in randomized clinical trials
Buyse M. Invited Educational Session at the 21st International Congress on Anti-Cancer Treatment (ICACT).
Paris, France
January 22, 2010
PFS vs.OS.
Invited Lecture at the meeting "Coups de Coeur et controverses".
Paris, France
January 7, 2010
Sur quels critères se base-t-on pour juger de la nécessité d’inclure un produit ou une association de produits dans des recommandations : taux de rémissions objectives, survie sans rechute ou survie globale ?
Buyse M. Invited Lecture at the Premier Cours Francophone sur le Cancer du Sein en Situation métastatique.
Nice, France
- 2009
December 15, 2009
Critères d'efficacité en 1ère ligne métastatique du cancer du sein
Buyse M. Invited Lecture at the Rencontres de la Cancérologie Française, Cité Universitaire Internationale de Paris.
Paris, France
November 20, 2009
Statistical considerations for cancer trial endpoints
Buyse M. Invited lecture at the "Best of Oncology" meeting.
Olos, Finland
November 18, 2009
General considerations in choosing endpoints for cancer clinical trials
Buyse M. Invited lecture at the PSI meeting "Design and analysis of oncology studies".
London, UK
November 11, 2009
On trial endpoints that combine clinical relevance and statistical efficiency
Buyse M. Keynote lecture at the National Launch Meeting of MRC Hubs.
London, UK
October 29, 2009
Considerations for interim analyses in seamless phase II/III trials
Buyse M. Invited lecture at the Swiss Group for Clinical Cancer Research Symposium.
Zurich, Switzerland
October 16, 2009
Validation of statistically reliable biomarkers
Buyse M. Speaker at the 3rd EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer.
Brussels, Belgium
October 16, 2009
Méta-analyses
Buyse M. Invited lecture at the 1ère Université d'Automne du Cercle de Réflexion de l'Oncologie Libérale.
Cannes, France
October 7, 2009
Randomized phase II trials: are they really better?
Buyse M. Invited lecture at the National Cancer Research Institute Conference.
Birmingham, UK
October 4, 2009
The use of biomarkers in cancer clinical trials
Buyse M. Invited plenary lecture at the National Cancer Research Institute Conference.
Birmingham, UK
September 24, 2009
The role of randomized trials and surrogate biomarkers in early clinical development.
Buyse M. Speaker at the ECCO 15-34th ESMO at the Special Session on Trial Methodology .
Berlin, Germany
September 20, 2009
This house believes that traditional phase II trials are a waste of time and money
Buyse M. Oxford Style Debate at the Joint ECCO15 – 34th ESMO Multidisciplinary Congress.
Berlin, Germany
September 5, 2009
Sensible Guidelines for the Conduct of Clinical Trials.
Buyse M. Chairperson at the Session II: "Overcoming Barriers to Conducting Trials". St Anne's College, Oxford, UK.
Oxford, UK
September 2, 2009
Methodology in trial design and meta-analysis
Buyse M. Invited lectures at the Vito Distante Project in Breast Cancer Clinical Research.
Scarperia, Italy
August 23, 2009
On trial endpoints that combine clinical relevance and statistical efficiency
Buyse M. President invited Lecture of the International Society for Clinical Biostatistics for the 30th Annual Meeting.
Prague, Czech Republic
July 24, 2009
Validation of surrogate markers and endpoints in clinical trials
Buyse M. Invited lecture at the Biostatistics Workshop in Cancer Research at the University of Toronto.
Toronto, Canada
June 26, 2009
Meta-Analysis and Validation of Surrogate Endpoints.
Tomas Burzykowski, speaker at the European Statistical Meeting on Meta-Analysis. A one day European meeting Statistical Meeting organised by the Basel Biometric Section (BBS) in cooperation with the Federation of Statisticians in the Pharmaceutical Industry ( EFSPI).
Basel, Switzerland
June 25, 2009
Challenges in using progression-free survival as and endpoint in randomized clinical trials in cancer
Buyse M. Invited lecture at the ARCAD Scientific Meeting
Barcelona, Spain
June 25, 2009
Issues and challenges in choosing endpoints for phase III clinical trials
Buyse M. Invited lecture at the ESMO Conference at the Session IV: "Cancer of the Liver" : 11th World Congress on Gastrointestinal Cancer.
Barcelona, Spain
June 4, 2009
Six-year outcomes update from a randomized phase 3 trial in AML: Durable effect of remission maintenance immunotherapy with histamine dihydrocholoride and low-dose IL-2.
Brune ML, Hellstrand K, Buyse M, Squifflet P, Allard SE, Castaigne S, Rowe JM. Abstract submitted to the 14th Congress of the European Hematology Association.
Berlin, Germany
June 2, 2009
The changing landscape of interim analyses for efficacy/futilility
Buyse M. Invited lecture at the Massachusetts Biotechnology Council.
Cambridge, US
May 20, 2009
Adaptation: Who decides?
Buyse M. Chair at the Plenary Session on "Adaptation: Who decides?": Use of Independent Data Monitoring Committees in Adaptive Trial Designs at the PSI 32nd Annual Conference.
Brighton, UK
May 17, 2009
Challenges in using progression-free survival as a surrogate for survival in randomized clinical trials in cancer
Buyse M. Invited lecture at the PSI 32nd Annual Conference.
Brighton, UK
May 9, 2009
PFS as a surrogate of OS in studying new treatments of solid tumors
Buyse M. Invited lecture at the Kidney Cancer Association’s 4th European Kidney Cancer Symposium.
Berlin, Germany
May 7, 2009
Methodology in biomarkers research and validation
Buyse M. Invited lecture at the pre-IMPAKT Breast Cancer Conference Training Course " My journey with new technologies: all I wanted to know and never dared to ask".
Brussels, Belgium
May 3, 2009
Surrogate Outcomes : Getting beyond the basics.
Buyse M. Invited course at Annual Meeting of the Society of Clinical Trials .
Atlanta, US
May 3, 2009
Fellows Session
Buyse M. Invited lecture at the Annual Meeting of the Society for Clinical Trials.
Atlanta, US
April 30, 2009
Quality assurance in clinical trials
Buyse M. Invited lecture at the Clinical Trials House of the University of Leeds.
Leeds, Leeds, UK
March 11, 2009
Essais de phase II et III en cancérologie.
Buyse M. Invited lectures at the Seminar « Formation des Oncologues
à la Recherche Clinique d'Excellence ».
Fontenay Tresigny, France
January 28, 2009
Can statistical analysis reveal research misconduct?
Buyse M. Rapporteur at the European Forum for Good Clinical Practice Annual Conference on Research Integrity
Prague, Czech Republic
January 15, 2009
Coordinated analyses of the five groups of experts of the RPC.
Buyse M. Invited Discussant at the 11ème cours Francophone Superieur sur le Cancer du Sein.
Saint Paul de Vence, France
- 2008
November 27, 2008
AZ Oncology Clinical Trials Workshop
M. Buyse, Invited Faculty.
Singapore
October 27, 2008
Invited lecture at the Progrssion-free survival (PFS) Canadian Oncology Societies (COS) Workshop
Toronto
October 10, 2008
How to define predictive and/or prognostic factors: levels of evidence?
Buyse M. Invited lecture at the Prognosis and Prediction In Breast Cancer Congress.
Monaco
October 8, 2008
On the Need for External Validation in Biomarker Research
Buyse M. Invited lecture at the satellite workshop post to the Cochrane Colloquium.
Freiburg, Germany
September 30, 2008
European Union Clinical Trials Directives
Danielson L. Invited lecture at the ARVO one day course at EVER on Design, conduct and management of clinical trials in eye research.
Portoroz, Slovenia
September 26, 2008
External validation in biomarker research: Examples from gene profiling in early breast cancer
Buyse M. Invited lecture at the The Steele Laboratory Integrative Tumor Biology Seminar Series.
Massachusetts General Hospital Cancer Center, MA, Boston, US
September 22, 2008
Statistical issues in identifying, validating and using molecular markers in clinical trials
Buyse M. Invited lectures at the Third Annual AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
Philadelphia, PA, US.
September 1, 2008
Clinical Trial Methodology
Buyse M. Invited lectures at the Australia and Asia Pacific Clinical Oncology Research Development ACORD Workshop,
Brisbane, Australia
July 5, 2008
Biomarkers and surrogate endpoints in clinical research - some statistical challenges
Buyse M. Invited lecture at the 20th Meeting of the European Association for Cancer Research.
Lyon, France.
July 3, 2008
Surrogate Endpoints:Balancing the Objectives of Patients, Industry and Regulators
Buyse M. Invited lecture at the European Course for Pharmaceutical Medicine,
Basel Switzerland
June 30, 2008
Designs for randomized clinical trials, and methods of randomization
Buyse M. Invited lecture at the European Course for Pharmaceutical Medicine,
Basel, Switzerland
June 23, 2008
Meta Analysis
Dr. Buyse, invited lecture at the 2008 Edition of the Summer School On Modern Methods in Epidemiology and Biostatistics ,
Courses on both introductory and more advanced epidemiology and biostatistics, given in a two week program, will be run by faculties from Harvard School of Public Health and Karolinska Institutet. In this edition few more courses are added: Meta-Analysis, Monitoring and Evaluation of Health Programs, and Evidence Based Public Health. All courses will be using Stata. Visit the course homepage for more information about the course http://www.biostatepi.org .Treviso, Italy
June 12, 2008
Fraud and errors in clinical research - what matters and what does not
Buyse M. Invited lecture at the International Scientific Meeting of the Association of Clinical Pathologists.
Prague, Czech Republic
June 4, 2008
An overview of biomarker identification and use in clinical research
Buyse M. Invited lecture at the PSI meeting "Decision making in clinical trials"
London, UK
June 2, 2008
Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: evidence from a pooled analysis of 2838 patients randomized in 7 trials
Buyse M. Invited lecture at the ASCO,
Chicago, IL, US
May 29, 2008
Benefits and Risks : Optimizing Decisions by Information Synthesis
Buyse M. Invited Speaker at the Harvard Schering Plough Workshop : Benefits and Risks : Optimizing Decisions by Information Synthesis.
Boston, MA, US
May 7, 2008
Methodology in biomarkers research and validation
Buyse M. Invited lecture at the pre-IMPAKT Training Course, “My journey with new technologies: all I wanted to know and never dared to ask.
Brussels, Belgium
April 12, 2008
Clinical Trials Design Workshop
Buyse M. Educational Session at the AACR Meeting.
San Diego CA, US
March 26, 2008
Essais de phase II et III en cancérologie
Buyse M. Invited lecture at the Seminar "Formation des Oncologues à la Recherche Clinique d'Excellence".
Normandie, France
January 29, 2008
Structure and programs for clinical trials in the French NCI
Buyse M. Invited lecture at the Conseil Scientifique de l'Institut National du Cancer.
Paris, France
January 24, 2008
Problems with the validation of biomarkers.
Buyse M. Invited lecture at the ARCAD Foundation Meeting.
Orlando, FL, US
- 2007
November 21, 2007
Statistical Alerts For Errors
Buyse M, Lefevre N. Invited lecture at the Applied Statitical Workshop, Université Catholique de Louvain.
Louvain-la-Neuve, Belgium
October 17, 2007
Factorial designs
Buyse M. Session chair at the DIA Statistical Meeting.
Madrid, Spain,
October 17, 2007
New developments in oncology
Buyse M. Invited lecture at the DIA Statistical Meeting.
Madrid, Spain
October 12, 2007
Minimization.
Buyse M. Invited lectures at GlaxoSmihKline.
Stockley Park, UK
September 27, 2007
Invited lecture at the meeting of the European Society of Coloproctology
Buyse M. Meeting of the European Society of Coloproctology September.
Valetta, Malta
September 23, 2007
Towards the validation of statistically reliable biomarkers.
Buyse M. Invited Educational Lecture at the 14th European Conference on Clinical Oncology.
Barcelona, Spain
September 11, 2007
Methods in meta-analysis.
Buyse M. Invited lecture at the 2007 Seminar der Internationalen Biometrischen Gesellschaft Region Österreich–Schweiz (ROeS).
Bern, Switzerland
August 27, 2007
Clinical trials and translational research.
Buyse M. Invited lecture at the Danish Society of Clinical Oncology.
Copenhagen, Denmark
August 26, 2007
Computer-intensive data checking in clinical trials
Buyse M. Invited lecture at the 27th Meeting of the International Society of Clinical Biostatistics.
Geneva, Switzerland,
June 25, 2007
Biomarkers and surrogate endpoints in clinical research - what levels of evidence do we need?
Buyse M. Invited lecture at the 28th Meeting of the International Society of Clinical Biostatistics.
Alexandroupolis, Greece
June 13, 2007
Validation of surrogate endpoints.
Buyse M. Invited tutorial at the PAGE meeting.
Copenhagen, Denmark
June 1, 2007
Endpoints in adjuvant trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.
Buyse M, Punt CJA, Köhne CH, Hohenberger P, Labianca R, Schmoll HJ, Pahlman L Sobrero A, Douillard JY. Poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology.
Chicago, IL, US
May 8, 2007
Fast and sensitive trials: new paradigms in clinical research.
Buyse M. Invited lecture at the International Biometric Society First Channel Network Conference.
Rolduc, the Netherlands
April 21, 2007
Validation of molecular markers for clinical use.
Buyse M.Invited Lecture.
Vejle, Denmark
April 12, 2007
Fast and sensitive trials: new paradigms in clinical research.
Buyse M. Invited lecture at the Grand Medical Round, Asan Medical Center.
Seoul, Korea
March 26, 2007
Minimization: much ado about nothing?
Buyse M. Invited discussion at the EuroDIA Meeting.
Vienna, Austria
March 21, 2007
Quality assurance in clinical trials.
Buyse M. Invited lecture at the SEARCH Collaborator Meeting.
Oxford, United Kingdom
January 26, 2007
Critical aspects of clinical trials.
Buyse M. Invited lecture at the Meeting on Sensible guidelines for the Conduct of Clinical Trials.
Washington DC, US
- 2006
December 2, 2006
Bias and power, the two central statistical concepts in clinical trials.
Buyse M. Invited lecture at the Women's Health Congress.
Basel, Switzerland
October 14, 2006
Cours sur les essais cliniques en cancérologie.
Buyse M. Invited course at the Rencontres d’Oncologie Astra-Zeneca.
Mont-Saint-Michel, France
October 6, 2006
Les Stratégies moléculaires ameliorent-elles nos décisions thérapeutiques?
Buyse M. Invited lecture at the 9èmes Rencontres d'Oncologie des Baux de Provence.
les Baux de Provence, France,
October 5, 2006
Etudes Cliniques, vers une qualité raisonnée des données
Buyse M. Invited lecture at the Centre International de Recherche sur le Cancer.
Lyon, France
October 3, 2006
Analysis of ocaliplatin reintroduction in patients with advanced colorectal cancer (CRC) treated with FOLFOX4 or FOLFOX7 in the OPTIMOX study.
de Gramont A., Buyse M., Cervantes A., Figer A., Lledo G., Flesh M., Mineur L., Carola E., Etienne P.L., Rivera F., Chirivella I., Perez-Staub N., Louvet C., André T., Tabah-Fisch I., Cortinas Abrahantes J., Quinaux E., Tournigand C. Paper submitted to the 31st ESMO Congress.
Istanbul, Turkey
September 29, 2006
Validation of surrogate endpoints using meta-analyses of individual patient data
Molenberghs G., Alonso A., Buyse M. Invited lecture at the FDA.
Washington, DC, USA
September 3, 2006
Clinical trial methodology.
Buyse M. Invited lectures at the Australia and Asia Pacific Clinical Oncology Research Development (ACORD) Workshop.
Brisbane, Australia
July 16, 2006
Validation of surrogate endpoints using meta-analyses of individual patient data.
Buyse M. Invited lecture at the 23rd International Biometric Conference.
Montreal, Quebec, Canada
July 14, 2006
Elevated Neutrophil Elastase mRNA is associated with Poor Outcome in Primary Breast Cancer Patients with high Cyclin E levels.
Desmedt C., El Ouriaghli F., Durbecq V., Soree A., Colozza M.A., Azambuja E., Paesmans M., Larsimont D., Buyse M., Harris A., Piccart M., Martiat P., Sotiriou C. Abstract submitted the AACR Special Conference on Breast Cancer.
La Jolla, CA, US
June 6, 2006
Phase II clinical trial design in 2006
Eisenhauer E., Simon R., Buyse M. Educational Session at the ASCO Meeting.
Atlanta, Georgia, US
May 18, 2006
Nouvelle organisation de la recherche clinique et implication des groupes de patients.
Buyse M. Invited lecture at the 6èmes Journées du Groupe Français des Myélodysplasies.
Marseille, France,
May 5, 2006
Early stopping rules in clinical trials: what can we learn from recent examples?
Buyse M. Invited lecture at the 2nd Annual Meeting of Cancer Clinical Trials Unit.
London, United Kingdom
May 3, 2006
Using randomized clinical trials to study biomarkers.
Buyse M. Invited lecture at the workshop on design of biomarker studies in clinical trials: potential and pitfalls
Oxford, United Kingdom
April 26, 2006
Surrogates endpoints in advanced ovarian cancer
Buyse M. Invited presentation at the FDA / ASCO / AACR Ovarian Cancer End Points Workshop, April 26, 2006.
Washington DC, US,
April 6, 2006
Surrogates and biomarkers in rare diseases
Buyse M. Invited lecture at the Eudipharm / EMEA Seminar on "Evaluation of Drugs in Rare Diseases".
London, United Kingdom
April 1, 2006
Que doit-on penser des études épidémiologiques? Traitements hormonaux substitutifs de la ménopause et cancer du sein : la tyrannie des chiffres.
Buyse M. Invited lecture at the Menop'Tech Seminar.
Brussels, Belgium,
March 21, 2006
Statistical issues for cancer clinical trials in the elderly
Buyse M. Invited lecture at the 5th European Breast Cancer Conference.
Nice, France
March 21, 2006
Statistical challenges in the design of the new generation of clinical trials.
Buyse M.Invited lecture at the 5th European Breast Cancer Conference.
Nice, France
March 17, 2006
Molecular predictors of response - validation of molecular markers.
Buyse M. Invited lecture at Arena Conference.
Oslo, Norway
March 15, 2006
L’Institut National du Cancer.
Buyse M. Invited lecture at the Séminaire Fédéral de Recherche Clinique.
Paris, France
March 9, 2006
L'Insitut National du Cancer
Buyse M. Invited lecture at the 12ème Journées du Groupe d'Etude des Lymphomes de l'Adulte.
Dijon, France
February 25, 2006
Politique de l'INCa en recherche clinique
Buyse M. . Invited lecture at the Séminaire Recherche Clinique du Cancéropôle Ile-de-France, Maison de la Chimie.
Paris, France,
February 24, 2006
Recherche clinique en cancérologie
Buyse M. Invited lecture at the Journées Scientifiques et Médicales de l'Institut Curie,
Paris, France
February 12, 2006
Statistical aspects in the interpretation of recent results on the adjuvant therapy in colon cancer.
Buyse M. Invited lecture at the European Multidisciplinary Colorectal Cancer Congress.
Berlin, Germany
February 2, 2006
Table Ronde sur la recherche clinique,
Buyse M. International Congress on Anti-Cancer Therapy.
Paris, France
February 2, 2006
Surrogate endpoints in breast cancer trials.
Buyse M. Invited lecture at the Conference "Breast Cancer: From Genes to Cure".
Amsterdam, The Netherlands,
January 19, 2006
Quelle organisation de la recherche clinique dans les CHU et les CH?
Buyse M. Invited lecture at the Premières Assises de Cancérologie de l’Hospitalisation Publique.
Paris, France
- 2005
December 12, 2005
Principe de précaution, éthique médicale et recherche clinique
Buyse M. Table Ronde au Colloque "Cancer : de l'utilité du principe de précaution" de l'Institut National du Cancer, Ministère de la Santé.
Paris, France
December 2, 2005
What phase III and meta-analyses can and cannot tell us.
Buyse M. Invited session at the European School of Oncology Colorectal Cancer Symposium.
London, United Kingdom
November 12, 2005
Interim analysis of breast cancer trials: opportunities and difficulties.
Buyse M. Invited lecture at the Pfizer Advisory Board.
Toronto, Canada,
October 30, 2005
Threats of interim analysis.
Buyse M. Invited lecture, ECCO 13.
Paris, France
October 7, 2005
Randomized phase II cancer clinical trials.
Buyse M. Invited lecture.
Osaka, Japan
October 6, 2005
Evolution for chemotherapy in advanced colorectal cancer.
Buyse M. Invited Lecture at the FLIGHT kick-off meeting.
Hirohsima, Japan,
October 5, 2005
Ask the Big Oncologist.
Buyse M. Interview in Kyoto, Japan.
Kyoto, Japan
September 29, 2005
Statistical approaches to quality assurance.
Buyse M. Invited paper presented at the 10th International Symposium on Long-Term Clinical Trials.
Oxford, United Kingdom
September 26, 2005
Statistical innovations in clinical trials
Buyse M. Inaugural address to the Fifth International Meeting on Statistical Methods in Biopharmacy.
Paris, France,
September 26, 2005
Challenges in the design of the MINDACT (Microarray In Node negative Disease may Avoid Chemotherapy) trial (EORTC 10041 - BIG/TRANSBIG 3-04)
Bogaerts J., Buyse M., Cardoso F., Therasse P., Rutgers E., van't Veer L., Piccart M. Paper presented at the Fifth International Meeting on Statistical Methods in Biopharmacy.
Paris, France
September 26, 2005
Gene expression profiling in breast cancer challenges the existence of intermediate histological grade.
Sotiriou C., Wirapati P., Loi S., Harris A., Bergh J., Smeds J., Praz V., Farmer P., Haibe-Kains B., Lallemand F., Buyse M., Piccart M., Delorenzi M. Paper presented at the Fifth International Meeting on Statistical Methods in Biopharmacy.
Paris, France
September 26, 2005
Re-randomization tests after minimization.
Jehl V., Quinaux E., Sturbois G., Buyse M. Paper presented at the Fifth International Meeting on Statistical Methods in Biopharmacy.
Paris, France,
September 5, 2005
Learning from the past and designing better trials for the future.
Buyse M. Invited lecture presented at the EORTC Course on Cancer Clinical Trials: Methods and Practice, September 5-9, 2005.
Brussels, Belgium,
August 26, 2005
What is clinically relevant for the urologist?
Buyse M.Invited lecture presented at the Prostate Cancer Conference for Norwegian Urologists.
Bergen-Bodø, Norway
August 1, 2005
The Importance of statistics
Buyse M. Invited lecture presented at the Elective Course in Oncology.
Antwerpen, Belgium
May 26, 2005
Design of trials with interim analyses.
Buyse M. Invited lecture at the Meeting of Cancer Center Statisticians.
Nancy, France
May 26, 2005
Innovative trial designs using genomic information
Buyse M. Invited lecture at the Meeting of Cancer Center Statisticians.
Nancy, France
May 15, 2005
Breaking from tradition in the design of phase III clinical trials.
Piccart M., Buyse M. Educational Session at the ASCO Meeting.
Orlando, Florida
March 17, 2005
Phase I trials in oncology
Buyse M. Invited lecture at the First Joint Meeting of the AGAH and the Club Phase I.
Strasbourg, France
March 15, 2005
Interim analyses and early stopping of clinical trials
Buyse M. IDDI Seminar.
Paris, France
March 12, 2005
Statistical view on stage II
Buyse M. Invited lecture at the Fourth International Eloxatin Meeting
Lisbon, Portugal
March 4, 2005
Clinical research: evolution or revolution?
Buyse M. Invited lecture at the Meeting of the Scientific Advisory Board, Insitut National du Cancer.
Paris, France
March 2, 2005
Statistical challenges in the validation of surrogate endpoints.
Buyse M. Invited lecture at the IIR Conference on phase III clinical trials in oncology.
Amsterdam, The Netherlands
February 3, 2005
Six key statistical issues in cancer clinical trials
Buyse M.Invited Lecture at the St Gallen Conference 2005.
St Gallen, Switzerland
- 2004
November 19, 2004
Three-year disease-free survival is a valid surrogate for 5-year survival in the adjuvant treatment of colorectal cancer
Buyse M. Invited lecture at the themadag of the Dutch Collaboration for Medical Oncology.
Ede, The Netherlands
November 16, 2004
Utilisation de la méta-analyse pour la validation des critères de substitution
Buyse M. Invited lecture at the Congrès Annuel du Groupe Biopharmacie et Santé de la Société Française de Statistique.
Paris, France
November 10, 2004
Traitements hormonaux de la ménopause et risque de cancer du sein : la tyrannie des statistiques
Buyse M. Invited lecture at the 26èmes Journées de la Société Française de Sénologie et de Pathologie Mammaire.
Nancy, France
November 9, 2004
Interim analyses and early stopping of clinical trials
Buyse M. IDDI Seminar.
London, United Kingdom
October 29, 2004
How to progress? A statistician's view.
Buyse M. Invited lecture at the ESMO Symposium on Changing Standards in Early Stage Colon Cancer.
Vienna, Austria
October 21, 2004
Interim analyses and early stopping of clinical trials
Buyse M. IDDI Seminar.
Boston, MA, US
September 29, 2004
Is disease-free survival good enough to confirm benefit from adjuvant therapy?
Buyse M., Cunningham D. Invited lecture at the Symposium on Key Advances in the Effective Management of Colorectal Cancer, Royal College of Physicians of London.
London, United Kingdom
September 22, 2004
Statistical challenges in the validation of surrogate endpoints.
Buyse M. Invited paper presented at the FDA / Industry Workshop.
Bethesda, MD, US
September 22, 2004
Statistical issues with minimization: unpredictability, balance, size, and power.
Buyse M. Invited paper presented at the FDA / Industry Workshop.
Bethesda, MD, US
September 7, 2004
Three-year disease-free survival is a valid surrogate for 5-year survival in the adjuvant treatment of colorectal cancer
Buyse M. Invited lecture at the Symposium on Adjuvant Colorecal Cancer.
London, United Kingdom
August 8, 2004
Clinical trial Methodology
Buyse M. Invited lectures at the Australia and Asia Pacific Clinical Oncology Research Development (ACORD) Workshop.
Melbourne, Australia
July 12, 2004
Designs for randomized clinical trials, and methods of randomization
Buyse M.Invited lecture at the European Course for Pharmaceutical Medicine.
Basel, Switzerland
July 6, 2004
Three-year disease-free survival is a valid surrogate for 5-year survival in the adjuvant treatment of colorectal cancer
Buyse M. Invited lecture at the Meeting on Treating Adjuvant Colon Cancer.
London, United Kingdom
June 19, 2004
Interim analysis
Buyse M. Course organized by the Federation of European Cancer Societies, the American Association for Cancer Research and the American Society for Clinical Oncology.
Flims, Switzerland
May 28, 2004
Trends in the design of phase II cancer trials
Buyse M.IDDI Seminar.
Copenhagen, Denmark
April 29, 2004
Trends in the design of phase II cancer trials
Buyse M.IDDI Seminar.
New York, NY, US
April 14, 2004
Design of the TRANSBIG/EORTC trial using molecular profiling
Piccart M.J., Rutgers E., van 't Veer L., Sotiriou C., Smeds J., Buyse M., Straehle C. and Cardoso F.Paper submitted to the 3rd EORTC/NCI Conference on New Drugs.
Frankfurt, Germany
April 7, 2004
endpoints, interim analyses and flexible trial designs.
Buyse M. Multiple Invited lecture at the IIR Conference on Phase III Clinical Trials in Oncology, Evolving Guidelines and Innovations for Targeted Therapies.
Amsterdam, The Netherlands
April 1, 2004
General considerations in the design of clinical trials, data management, analysis and reporting of data
Buyse M. Information technology in clinical trials. Invited lectures at the Educational Workshop on the Value and Conduct of Clinical Trials in Brazil.
Sao Paulo, Brazil
March 16, 2004
Chairperson in the Oxford Union Style Debate
Buyse M. 4th European Breast Cancer Conference.
Hamburg, Germany
March 2, 2004
Trends in the design of phase II cancer trials
Buyse M.IDDI Seminar.
Boston, MA, US
February 26, 2004
Applying advanced statistical methodologies to optimize clinical trial design
Buyse M. . Invited lecture at the IQPC Conference on Optimizing Clinical Trial Design in Oncology.
London, United Kingdom
February 6, 2004
Adaptation of design in early drug development
Buyse M. Invited workshop at the 6th Meeting of the Club Phase I.
Paris, France
January 27, 2004
Patients as volunteers in phase I: assessing the applicability of the oncology approach to phase I in other therapeutic areas
Buyse M. Invited lecture at the IIR Conference on Phase I Studies.
Washington DC, US
January 21, 2004
Trends in the design of phase II cancer trials
Buyse M.,IDDI Seminar.
Paris, France
- 2003
November 24, 2003
The Design and analysis of clinical trials
Buyse M. Invited course organized by the Centro Nacional Coordinador de Ensayos Clinicos.
La Havana, Cuba
November 4, 2003
Trends in the design of phase II cancer trials
Buyse M. IDDI Seminar.
Montreal, Canada
October 13, 2003
Innovative early phase trial design for targeted anti-cancer drugs
Buyse M. Invited lecture at the IBC Workshop.
London, United Kingdom
June 30, 2003
Trends in the design of phase II cancer trials
Buyse M. IDDI Seminar.
London, United Kingdom
June 24, 2003
Clinical Trials
Buyse M. Course organized by the Mediterranean School of Medical Statistics and Clinical Epidemiology.
Siracusa, Italy
June 21, 2003
Interim analysis
Buyse M.Course organized by the Federation of European Cancer Societies, the American Association for Cancer Research and the American Society for Clinical Oncology.
Flims, Switzerland
June 21, 2003
Cornerstones of a well-designed phase III trial
Buyse M. Invited lecture at the European Cancer Conference.
Copenhagen, Denmark
June 20, 2003
Impact of monitoring visits on patient recruitment and data quality: case study of a phase IV trial in oncology
Quinaux E., Liénard J.L., Slimani Z., Jouhaud A., Piedbois P., Buyse M. Poster presented at the Joint Meeting of the International Society of Clinical Biostatistics and the Society for Clinical Trials.
London, United Kingdom
June 20, 2003
The Validation of surrogate endpoints in clinical trials.
Buyse M., Molenberghs G., Burzykowski T. Pre-conference course at the Joint Meeting of the International Society of Clinical Biostatistics and the Society for Clinical Trials.
London, United Kingdom
June 15, 2003
Individual-level and trial-level surrogacy
Buyse M. Invited lecture at the DIA Annual Meeting.
San Antonio, TX, US
June 11, 2003
Data Management
Buyse M. Invited lecture at the SMi Conference on Clinical Trials in Cancer.
London, United Kingdom
June 4, 2003
Statistics
Buyse M. Invited lectures at the Basic Course in Medical Oncology, European Society of Medical Oncology.
Warsaw, Poland
March 21, 2003
Rationale for a meta-analysis
Buyse M.Invited lecture at the AERO Conference on paclitaxel in the adjuvant treatment of breast cancer.
Beaune, France
March 8, 2003
Existing evidence: from review to meta-analysis.
Buyse M.Course given in the Doctoral Study Program in Medical Science, Universitaire Stichting.
Brussels, Belgium
January 31, 2003
Méthodologie des essais cliniques en oncologie.
Buyse M.Course organized by Astra-Zeneca and Association Européenne de Recherche en Oncologie.
Paris, France
January 20, 2003
Endpoints for phase III trials.
Buyse M. Invited lecture at the IIR Conference on Phase III Clinical Trials in Oncology.
London, United Kingdom
- 2002
December 14, 2002
Contributions of meta-analysis to the treatment of colorectal cancer.
Buyse M. Invited lecture at the 24th Annual Meeting of the Society for Clinical and Biostatistical Research.
Kyoto, Japan
December 11, 2002
Randomized phase II trials.
Buyse M. Invited lecture at Kyoto University.
Kyoto Japan
December 10, 2002
Validation of surrogate endpoints in cancer clinical trials.
Buyse M. Invited lecture at Kyoto University.
Kyoto, Japan
July 21, 2002
Surrogate marker validation.
Buyse M. Chair and Discussant of an Invited Session at the 21st International Biometric Conference.
Freiburg, Germany
July 8, 2002
Designs for randomized clinical trials, and methods of randomization.
Invited lecture at the European Course for Pharmaceutical Medicine.
Basel, Switzerland
June 30, 2002
Randomized phase II trials.
Buyse M. Invited lecture at the 18th UICC International Cancer Congress, June 30-July 5, 2002. Int J Cancer Suppl 13: 4, Abstract I7, 2002.
Oslo, Norway
June 30, 2002
Surrogate endpoints in early trials.
Invited lecture at the 18th UICC International Cancer Congress. Int J Cancer Suppl 13: 35, Abstract I107, 2002.
Oslo,Norway
June 23, 2002
Interim analysis
Buyse M.Course organized by the Federation of European Cancer Societies, the American Association for Cancer Research and the American Society for Clinical Oncology.
Flims, Switzerland
June 20, 2002
Contributions of meta-analysis to the treatment of colorectal cancer.
Buyse M. Keynote lecture at the International Conference on Colorectal Cancer.
Barcelona, Spain
May 12, 2002
Access to data from randomized clinical trials: why we need it.
Buyse M. Invited session at the 23rd Meeting of the Society for Clinical Trials, Controlled Clin Trials 23: 17S, 2002
Arlington, Virginia, US
March 29, 2002
General considerations in the design of clinical trials, data management, and analysis and reporting of data.
Buyse M. Invited lectures at the Educational Workshop on the Value and Conduct of Clinical Trials in China.
Beijing, China
March 23, 2002
Combinability of Cytotoxics.
Buyse M. Invited Lecture at the Eloxatin International Symposium.
Budapest, Hungary
March 14, 2002
Statistics in Clinical Trials.
Buyse M. Invited Lecture at the ESMO Course in Medical Oncology,Russian Federation.
St Petersburg, Russia
March 9, 2002
Lecture critique des méta-analyses.
Buyse M.Invited paper at the Symposium Stratégies en hormonothérapie des cancers du sein: 25 ans d'acquis, et perspectives.
Venise, italy
- 2001
December 10, 2001
Clinical Biomarker Study Design III: Academic Perspective.
Buyse M. Invited paper at the International Conference on Optimising Drug Development: Use of Biomarkers from Drug Discovery through Clinical Practice, European Federation for Pharmaceutical Sciences (EUFEPS.
Basel, Switzerland,
October 21, 2001
Update on meta-analysis.
Buyse M. Invited session at the 11th European Conference on Clinical Oncology.
Lisbon, Portugal
October 12, 2001
Is survival an appropriate endpoint in advanced colorectal cancer?
Buyse M. Invited lecture at the Eloxatin Symposium.
Nice, France,
September 23, 2001
Response and survival in advanced colorectal cancer.
Buyse M.
Istanbul, Turkey
September 8, 2001
Clinical Trials
Buyse M.Course for EUDIPHARM.
Lyon, France
September 3, 2001
Clinical Trials
Buyse M. Course organized by the Mediterranean School of Medical Statistics and Clinical Epidemiology.
Isola Capo Rizzuto, Italy,
August 19, 2001
The Surrogate Threshold Effect - A new measure of the validity of a surrogate endpoint
Burzykowski T., Buyse M., Molenberghs T. Paper presented at the 22nd Meeting of the International Society of Clinical Biostatistics.
Stockholm, Sweden
August 19, 2001
Longitudinal data as surrogates for time-related endpoints
Renard D., Molenberghs T., Burzykowski T., Buyse M. Longitudinal data as surrogates for time-related endpoints. Paper presented at the 22nd Meeting of the International Society of Clinical Biostatistics.
Stockholm, Sweden
July 11, 2001
Statistical Modelling
Molenberghs G., Abad A., Abrahantes J.C., Geys H., Renard H., Shkedy Z., Tibaldi F., Buyse M. Paper submitted to the 16th International Workshop on Statistical Modelling.
Odense, Denmark,
June 23, 2001
Statistical overview of phase III clinical trials.
Buyse M.Course organized by the Federation of European Cancer Societies, the American Association for Cancer Research and the American Society for Clinical Oncology.
Flims, Switzerland
May 10, 2001
Meta-analysis.
Buyse M. Course for the Doctoraat Medische Wetenschappen, Royal Academy of Medicine.
Brussels, Belgium
March 25, 2001
The Use of minimization, and its impact on the statistical tests used to compare treatment arms.
Buyse M., Dubois C. Invited paper presented at the ENAR Meeting.
Charlotte, NC, US
March 11, 2001
Does initial response to treatment predict long term survival?
Buyse M. Invited lecture at the European Conference on Cancer Strategies and Outcomes.
Edinburgh, Scotland
March 10, 2001
Making sense of the trials.
Buyse M. Invited lecture at the European School of Oncology Conference on Colorectal Cancer.
London, United Kingdom,
February 22, 2001
The Methodology of clinical trials.
Buyse M. Course at Gilead Sciences.
Boulder, CO, US
February 7, 2001
Méta-analyse, aspects théoriques et cas concrets.
Buyse M. Course for the Diplôme Inter-Universitaire de Pharmaco-Epidémiologie.
Paris, France,
January 18, 2001
Les Bonnes pratiques cliniques en oncologie pédiatrique : l'essentiel et l'accessoire.
Buyse M. Invited lecture at the FRALLE/CLG-EORTC Meeting,Fondation Universitaire.
Brussels, Belgium,
- 2000
November 20, 2000
Fraud in clinical trials: a biostatistical perspective.
Buyse M. Invited lecture at the 10th Annual DIA Meeting on Clinical Data Management.
London, UK
November 15, 2000
Designing cancer trials from phase I to phase IV.
Buyse M. Invited lecture at the 1st International Workshop on the Design and Conduct of Clinical Trials.
Matanzas, Cuba
September 21, 2000
Tumor response vs tolerability vs PFS vs survival in colorectal cancer.
Buyse M. Invited lecture at the 2nd Strategy Meeting of the Chronotherapy Group of the EORTC.
St Raphaël, France,
September 1, 2000
Beyond estimation of treatment effects in meta-analyses of clinical trials.
Buyse M. Keynote lecture at MIE/GMDS2000 Conference.
Hannover, Germany
July 26, 2000
The Experience of planning and design of clinical trials in cancer.
Buyse M. Proceedings 68th Annual Meeting of the Japanese Statistical Society.
Sapporo, Japan
July 25, 2000
Data management and biostatistics at the International Institute for Drug Development
Buyse M. Invited lecture at the Meeting of the Study Group for Data Management
Tokyo, Japan
July 10, 2000
Designs for randomized clinical trials, and methods of randomization.
Buyse M. Invited lecture at the European Course for Pharmaceutical Medicine.
Basel, Switzerland
June 26, 2000
The Validation of surrogate endpoints from several randomized experiments.
Burzykowski T., Molenberghs G., Buyse M. Paper presented at the Seminar "Statistics and Clinical Practice", Warsaw, Poland, June 26-30, 2000.
Warsaw, Poland
June 24, 2000
Clinical trial design.
Buyse M. Course organized by the Federation of European Cancer Societies, the American Association for Cancer Research and the American Society for Clinical Oncology.
Flims, Switzerland
June 23, 2000
Relation réponses objectives et survie globale.
Buyse M. Invited lecture at the IIIè Symposium International de Langue Française "Oncologie.
Budapest , Hungary.
June 17, 2000
Statistical assessment of adjuvant chemotherapy in stage II colon cancer.
Buyse M. Invited lecture at the 4th International Conference on Colorectal Cancer.
Paris, France
June 5, 2000
Clinical Trials
Buyse M. Course organized by the Harvard School of Public Health and the Mediterranean School of Medical Statistics and Clinical Epidemiology.
Siracusa, Italy
March 19, 2000
The Evaluation of surrogate endpoints in meta-analyses of randomized clinical trials.
Buyse M. Invited paper presented at the ENAR Meeting, Chicago, IL, US, March 19-22, 2000.
Chicago, IL, USA
February 11, 2000
Méta-analyse, aspects théoriques et cas concrets.
Buyse M. Course for the Diplôme Inter-Universitaire de Pharmaco-Epidémiologie.
Paris, France
February 9, 2000
Randomisation centralisée et plans expérimentaux complexes.
Buyse M. Invited paper, Geneva Clinical Research Forum.
Geneva, Switzerland
January 26, 2000
Quoi de neuf sur la méthodologie en recherche clinique ?
Buyse M. Invited paper at the 4ème biennale monégasque de cancérologie, January 26-29, 2000.
Monaco
January 13, 2000
La Méta-analyse.
Buyse. M. Invited paper at Institut Jules Bordet.
Brussels Belgium